PurposeThe potential effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on the weight of girls with central precocious puberty (CPP) remains a controversy. We investigated anthropometric changes during and after GnRHa treatment among girls with CPP.MethodsThis retrospective study evaluated data from 127 girls with CPP who received GnRHa treatment for ≥2 years. Height, weight, and body mass index (BMI) values were compared at the baseline (visit 1), after 1 year of GnRHa treatment (visit 2), the end of GnRHa treatment (visit 3), and 6–12 months after GnRHa discontinuation (visit 4).ResultsThe height z score for chronological age (CA) increased continuously between visit 1 and visit 4. No significant differences were observed ...
Objective: The study aimed to assess the effect of gonadotropin-releasing hormone (GnRH) agonist the...
It has been reported that gonadotropin releasing hormone analogue (GnRHa) therapy can improve the ad...
OBJECTIVE:Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice for central pr...
Aim:Gonadotropin-releasing hormone agonists (GnRHa) are widely used in the treatment of central prec...
Gonadotropin-releasing hormone analogs (GnRHa) are widely used to treat central precocious puberty (...
Purpose This study investigated the influence of obesity on the clinical course and effect of gonado...
Purpose Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and aft...
PURPOSE: There is controversy surrounding the growth outcomes of treatment with gonadotropin-releasi...
Introduction: There are several concerns associated with gonadotropin-releasing hormone agonist (GnR...
PurposeGonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central pre...
Background/PurposeIt has been reported that gonadotropin releasing hormone analogue (GnRHa) therapy ...
PurposeTo investigate the effectiveness and safety of gonadotropin-releasing hormone analogue (GnRHa...
Objective: We assessed in a retrospective unicenter study the impact of treatment with GnRH analogs ...
BackgroundGonadotropin-releasing hormone analogs (GnRHas) are effective in increasing the final heig...
Objective: Gonadotropin-Releasing Hormone agonists (GnRHa) are used to improve the final adult heigh...
Objective: The study aimed to assess the effect of gonadotropin-releasing hormone (GnRH) agonist the...
It has been reported that gonadotropin releasing hormone analogue (GnRHa) therapy can improve the ad...
OBJECTIVE:Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice for central pr...
Aim:Gonadotropin-releasing hormone agonists (GnRHa) are widely used in the treatment of central prec...
Gonadotropin-releasing hormone analogs (GnRHa) are widely used to treat central precocious puberty (...
Purpose This study investigated the influence of obesity on the clinical course and effect of gonado...
Purpose Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and aft...
PURPOSE: There is controversy surrounding the growth outcomes of treatment with gonadotropin-releasi...
Introduction: There are several concerns associated with gonadotropin-releasing hormone agonist (GnR...
PurposeGonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central pre...
Background/PurposeIt has been reported that gonadotropin releasing hormone analogue (GnRHa) therapy ...
PurposeTo investigate the effectiveness and safety of gonadotropin-releasing hormone analogue (GnRHa...
Objective: We assessed in a retrospective unicenter study the impact of treatment with GnRH analogs ...
BackgroundGonadotropin-releasing hormone analogs (GnRHas) are effective in increasing the final heig...
Objective: Gonadotropin-Releasing Hormone agonists (GnRHa) are used to improve the final adult heigh...
Objective: The study aimed to assess the effect of gonadotropin-releasing hormone (GnRH) agonist the...
It has been reported that gonadotropin releasing hormone analogue (GnRHa) therapy can improve the ad...
OBJECTIVE:Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice for central pr...